Belgium's Prime Minister Bart de Wever attends the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / POOL / AFP via Getty Images) / Belgium OUT

Belgium's Prime Minister Bart de Wever (TopL) speaks to the press attends the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT

Belgium's Prime Minister Bart de Wever attends the opening of a new centre dedicated to accelerating vaccine development of British pharmaceutical company GSK in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / POOL / AFP via Getty Images) / Belgium OUT

This photograph shows the logo of British pharmaceutical company GSK on a facade during the opening of a new centre dedicated to accelerating vaccine development in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT

This aerial photograph shows a view of British pharmaceutical company GSK's new centre dedicated to accelerating vaccine development in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT

This photograph shows the logo of British pharmaceutical company GSK on an entrance during the opening of a new centre dedicated to accelerating vaccine development in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT

This photograph shows the logo of British pharmaceutical company GSK on an entrance during the opening of a new centre dedicated to accelerating vaccine development in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT

This photograph shows the logo of British pharmaceutical company GSK on an entrance during the opening of a new centre dedicated to accelerating vaccine development in Rixensart, on June 9, 2026. The British pharmaceutical giant GSK opens a new research centre in Belgium and also announced on June 9, 2026, that it had reached an agreement to acquire the US biopharmaceutical company Nuvalent, which specialises in the development of cancer therapies, "for $10.6 billion" (9.18 billion). (Photo by ERIC LALMAND / Belga / AFP via Getty Images) / Belgium OUT